{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:36:34Z","timestamp":1770492994321,"version":"3.49.0"},"reference-count":26,"publisher":"Scientific Scholar","content-domain":{"domain":["ruralneuropractice.com"],"crossmark-restriction":true},"short-container-title":["JNRP"],"abstract":"<jats:sec id=\"st1\"><jats:title>Objectives:<\/jats:title><jats:p>Neuromyelitis optica (NMO) is a severe central nervous system demyelinating disease caused by autoantibodies to anti-aquaporin-4 immunoglobulin-G (AQP4-IgG). Rituximab, a monoclonal antibody targeting CD20 cells, is effective in neuromyelitis optica spectrum disorder (NMOSD) in several observational studies and small randomized controlled trials. However, this includes both AQP4-IgG antibody positive and negative cases. Whether rituximab is more effective in seropositive NMO is unknown. The aim of the study was to determine the efficacy of rituximab in seropositive NMO.<\/jats:p><\/jats:sec><jats:sec id=\"st2\"><jats:title>Materials and Methods:<\/jats:title><jats:p>This single-center ambispective study with retrospective data collection and prospective follow-up included patients with NMOSD who were positive for AQP4-Ig-G and treated with rituximab. Efficacy outcomes assessed were annualized relapse rate (ARR), disability progression by expanded disability status scale (EDSS), very good outcome (defined as no relapse and an EDSS \u22643.5), and persistent antibody positivity. Safety was also monitored.<\/jats:p><\/jats:sec><jats:sec id=\"st3\"><jats:title>Results:<\/jats:title><jats:p>Between June 2017 and December 2019, 15 AQP4-IgG-positive cases were identified. The mean (\u00b1 SD) age was 36 \u00b1 17.9 years and 73.3% were females. Transverse myelitis followed by optic neuritis was the most common presentations. Rituximab was initiated after a median period of 19-weeks from the disease onset. The mean number of rituximab doses received was 6.4 \u00b1 2.3. After a mean follow-up duration of 107 \u00b1 74.7 weeks from the first dose of rituximab, ARR significantly reduced from 0.5 \u00b1 0.9 to 0.02 \u00b1 0.08, difference 0.48 \u00b1 0.86 (95% confidence intervals [CI], 0.0009\u20130.96;<jats:italic>P<\/jats:italic>= 0.05). The number of relapses also reduced significantly from 0.6 \u00b1 0.8\u20130.07 \u00b1 0.26 , a difference of 0.53 \u00b1 0.91 (95% CI, 0.026\u20131.05;<jats:italic>P<\/jats:italic>= 0.041). EDSS also significantly reduced from 5.6 \u00b1 2.5\u20133.3 \u00b1 2.9 , a difference of 2.23 \u00b1 2.36 (95% CI, 0.93\u20133.54;<jats:italic>P<\/jats:italic>= 0.003). Very good outcome was obtained in 73.3% (11 of 15);<jats:italic>P<\/jats:italic>= 0.002. AQP4-IgG remained positive in 66.7% (4 of 6) when repeated after a mean period of 149.5 \u00b1 51.1 weeks after the first dose of rituximab. Neither pre-treatment ARR, EDSS, time to initiate rituximab, the total number of rituximab doses, or time to repeat AQP4-IgG were significantly associated with persistent antibody positivity. No serious adverse events were observed.<\/jats:p><\/jats:sec><jats:sec id=\"st4\"><jats:title>Conclusion:<\/jats:title><jats:p>Rituximab exhibited high efficacy and good safety in seropositive NMO. Larger trials in this subgroup are warranted to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.25259\/jnrp_59_2022","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T10:48:31Z","timestamp":1680691711000},"page":"327-332","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India"],"prefix":"10.25259","volume":"14","author":[{"given":"Joe","family":"James","sequence":"first","affiliation":[{"name":"Department of Neurology, Government Medical College Kozhikode, Kozhikode, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Abdul","family":"Gafoor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Government Medical College Kozhikode, Kozhikode, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jose","sequence":"additional","affiliation":[{"name":"Department of Neurology, Government Medical College Kozhikode, Kozhikode, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Smita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Government Medical College Kozhikode, Kozhikode, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neetha","family":"Balaram","sequence":"additional","affiliation":[{"name":"Department of Neurology, Government Medical College Kozhikode, Kozhikode, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"10.25259\/JNRP_59_2022\/ref-1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-2","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.25259\/JNRP_59_2022\/ref-3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"10.25259\/JNRP_59_2022\/ref-5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.25259\/JNRP_59_2022\/ref-6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.25259\/JNRP_59_2022\/ref-7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: A meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/aian.AIAN_499_16","article-title":"Rituximab in neuromyelitis optica spectrum disorders: Our experience","volume":"20","author":"Jade","year":"2017","journal-title":"Ann Indian Acad Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-14","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.25259\/JNRP_59_2022\/ref-15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/ene.12679","article-title":"Neuromyelitis optica: A positive appraisal of seronegative cases","volume":"22","author":"Bernard-Valnet","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1177\/1352458508088943","article-title":"Seronegative neuromyelitis optica: Improvement following lymphocytapheresis treatment","volume":"14","author":"Moreh","year":"2008","journal-title":"Mult Scler"},{"key":"10.25259\/JNRP_59_2022\/ref-17","doi-asserted-by":"publisher","first-page":"103926","DOI":"10.1016\/j.msard.2022.103926","article-title":"Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review","volume":"63","author":"Abbadessa","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.25259\/JNRP_59_2022\/ref-18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler"},{"key":"10.25259\/JNRP_59_2022\/ref-19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.25259\/JNRP_59_2022\/ref-20","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.25259\/JNRP_59_2022\/ref-21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.24208","article-title":"Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks","volume":"76","author":"Sato","year":"2014","journal-title":"Ann Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-22","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.25259\/JNRP_59_2022\/ref-23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.25259\/JNRP_59_2022\/ref-24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomized, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.25259\/JNRP_59_2022\/ref-25","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.25259\/JNRP_59_2022\/ref-26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomized placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ruralneuropractice.com\/therapeutic-response-to-rituximab-in-seropositive-neuromyelitis-optica-experience-from-a-tertiary-care-center-in-south-india\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ruralneuropractice.com\/therapeutic-response-to-rituximab-in-seropositive-neuromyelitis-optica-experience-from-a-tertiary-care-center-in-south-india\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T06:53:11Z","timestamp":1702191191000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/therapeutic-response-to-rituximab-in-seropositive-neuromyelitis-optica-experience-from-a-tertiary-care-center-in-south-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":26,"alternative-id":["10.25259\/JNRP_59_2022"],"URL":"https:\/\/doi.org\/10.25259\/jnrp_59_2022","relation":{},"ISSN":["0976-3155","0976-3147"],"issn-type":[{"value":"0976-3155","type":"electronic"},{"value":"0976-3147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"article-number":"327"}}